Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211821 | 0.83 | MAPT (0.50) | ADRB1MAPTSMN1; SMN2FFAR4PIK3CA | |
| SCHEMBL2734322 | 0.81 | SMN1; SMN2 (0.79) | MAPTSMN1; SMN2KDM4EALDH1A1MLYCD | |
| SCHEMBL27747094 | 0.80 | ADRB1 (0.62) | ADRB1MAPTFFAR4KDM4EALDH1A1 | |
| SCHEMBL30883140 | 0.79 | SERPINE1 (0.61) | MAPTSMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL210892 | 0.79 | PTGS1 (0.58) | MAPTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL18176129 | 0.76 | ADRB1 (0.73) | ADRB1MAPTFFAR4KDM4EALDH1A1 | |
| SCHEMBL24363082 | 0.75 | ADRB1 (0.68) | ADRB1MAPTFFAR4PIK3CAKDM4E | |
| SCHEMBL12968838 | 0.75 | ADRB1 (0.68) | ADRB1MAPTSMN1; SMN2FFAR4KDM4E | |
| SCHEMBL30883145 | 0.74 | XPO1 (0.52) | MAPTSMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL30883148 | 0.74 | FFAR4 (0.52) | MAPTSMN1; SMN2FFAR4PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | ADRB1 4612/4885MAPT 3612/4885SMN1; SMN2 3557/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | ADRB1 4609/4885MAPT 3905/4885SMN1; SMN2 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.